trial

Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.

NCTId NCT00239109
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 112
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
112
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-04
Primary completion
—
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
ZiprasidoneOlanzapineScalesmeasures of the body (Weight...)Serum analysis

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

7 total
Bilbao, SpainBadajoz, SpainBarcelona, SpainMadrid, SpainSalamanca, SpainSeville, SpainZamora, Spain

Facts & assertions

3 sourced
Enrollment
112
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
Olanzapine
drug
Scales
drug
measures of the body (Weight...)
drug
Serum analysis
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication